RE:Full report from Doug Loe"We expect to revisit our assumption on preferred target indication for TH1902 once we have Phase I tumor response data to review, probably near end-of-F2022 if the trial commences enrollment in early FQ321 as Thera predicts."
He's not expecting to see tumour response data until the end of 2022?